Angiochem to highlight oncology program data at 101st American Association for Cancer Research meeting

Angiochem, Inc., a clinical-stage biotechnology company developing drugs that are uniquely capable of crossing the blood-brain barrier through LRP targeting, announced today that preclinical data on two of its oncology programs, ANG1005 and ANG1007, for the treatment of brain cancers, as well as data demonstrating the utility of Angiochem's EPiC platform to achieve efficient penetration rates in the brain and in cancer tumor tissue, will be highlighted at the 101st Annual meeting of the American Association for Cancer Research 2010, April 17-21, in Washington, DC.

“Uptake of the new paclitaxel-derivative (ANG1005) by the low-density lipoprotein receptor-related protein1 (LRP1) is related to the aggressive phenotype of glioblastoma cells”

Poster Presentations:

  • Abstract #4417: Tuesday, April 20, 2010, 2:00 PM - 5:00 PM, "Uptake of the new paclitaxel-derivative (ANG1005) by the low-density lipoprotein receptor-related protein1 (LRP1) is related to the aggressive phenotype of glioblastoma cells," Bertrand, et.al., Exhibit Hall A-C, Poster Section 22, Poster Board 6
  • Abstract #3578: Tuesday, April 20, 2010, 9:00 AM - 12:00 PM, "New Angiochem-modified doxorubicin with increased brain penetration and efficacy against brain tumors," Demeule, et.al., Exhibit Hall A-C, Poster Section 24, Poster Board 26

Comments

The opinions expressed here are the views of the writer and do not necessarily reflect the views and opinions of News Medical.
Post a new comment
Post

While we only use edited and approved content for Azthena answers, it may on occasions provide incorrect responses. Please confirm any data provided with the related suppliers or authors. We do not provide medical advice, if you search for medical information you must always consult a medical professional before acting on any information provided.

Your questions, but not your email details will be shared with OpenAI and retained for 30 days in accordance with their privacy principles.

Please do not ask questions that use sensitive or confidential information.

Read the full Terms & Conditions.

You might also like...
Cleveland Clinic presents new findings on triple-negative breast cancer vaccine